梅瓦龙酸通过增强XA因子来产生促凝作用
Liyuan Niu1, Chuanfeng Liu2, Shaoying Wang3
1Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Natural products and bioprospecting
|January 10, 2026
概括
梅瓦龙酸 (MVA) 通过增强XA因子活性来加速血液凝固,从而增加血栓形成的风险. 这种脂质途径代谢物直接影响凝血,为代谢障碍提供新的治疗点.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 代谢途径 代谢途径
背景情况:
- 血栓瘤的发病包括脂质代谢和炎症.
- 在凝血过程中,梅瓦酸途径的作用尚不清楚.
研究的目的:
- 研究梅瓦龙酸 (MVA) 对凝血系统的调节作用.
- 阐明MVA对血液静止和血栓形成的直接影响.
主要方法:
- 重化试验和酶动力学分析,以确定MVA对凝血的影响.
- 在体内研究使用小鼠模型进行出血和血栓形成.
- 通过天然基质水解试验识别凝血目标.
主要成果:
- MVA通过强化Xa因子 (FXa) 凝血剂活性,显著加速血凝固.
- MVA缩短了激活的部分血栓塑时间和前血栓时间,减少了出血时间.
- 在铁化物诱导的血栓瘤,深静脉血栓瘤和脑梗塞模型中,MVA的使用增强了血栓的形成.
结论:
- 梅瓦龙酸直接调节FXa的凝血活性,将脂质代谢与凝血联系起来.
- 研究结果表明,脂质代谢和凝血中的炎症信号之间存在交叉关系.
- 梅瓦诺酸途径代表了代谢障碍中血栓性并发症的潜在治疗标.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis
11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
EDTA: Auxiliary Complexing Reagents
1.3K
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
1.3K


